Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Insight Molecular Diagnostics Inc
IMDX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.78
-0.08
-4.3%
In chiusura: Nov 17, 4:00 PM EST
$1.71
-0.15
-8.06%
Pre-mercato: 7:29 AM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data lun nov 16th, dopo la chiusura del mercato
Conference call:
La conference call più recente è iniziata alle 5:00 PM, 2 giorni fa
Clicca per vedere il webcast
Insight Molecular Financials
Insight Molecular (IMDX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
iMDx Says GraftAssureDx FDA Review Progressing; Preparing Response To FDA Request For Additional Information
Benzinga Newsdesk
PRO
Insight Molecular Diagnostics Q3 EPS $(0.10) Vs $(0.34) YoY; Rev $559K Vs $260K YoY
Benzinga Newsdesk
PRO
CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of $(0.30) per share from
Benzinga Newsdesk
PRO
Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of $(0.19) per share
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share
Benzinga Newsdesk